Table 3.
Age-stratified HPV results by cytology category for STRIDES individuals from the Mississippi State Department of Health (MSDH) before and after the institution changed to co-testing for women aged 30+
| n (%) = 16631 | ASC-US triage, Prior to July 1, 2018^ | Co-testing, After July 1, 2018^ | P-Value | ||
|---|---|---|---|---|---|
| HPV Results – Age 30+ | HPV Results – Age 30+ | ||||
| Cytology Category | Cytology (col %) | HPV + (row %) | Cytology (col %) | HPV + (row %) | |
| NILM | 1279 (87.8) | 5689 (89.2) | 775* (13.6) | ||
| ASC-US | 88 (6.0) | 27* (30.7) | 359 (5.6) | 144* (40.1) | 0.102 |
| LSIL | 43 (3.0) | 175 (2.7) | 100* (57.1) | ||
| ASC-H | 14 (1.0) | 21 (0.3) | 14* (66.7) | ||
| HSIL | 16 (1.1) | 78 (1.2) | 73 (93.6) | ||
| Endo/Glandular | 3 (0.2) | 9 (0.1) | 1* (11.1) | ||
| Inadequate | 13 (0.9) | 46 (0.7) | 4 (8.7) | ||
| Totals | 1456 | 27 (30.7) | 6377 | 1111 (17.4) | |
| HPV Results – Age <30 | HPV Results – Age <30 | ||||
| Cytology (col %) | HPV + (row %) | Cytology (col %) | HPV + (row %) | ||
| NILM | 1304 (78.9) | 5806 (81.3) | 4 (1.2) | ||
| ASC-US | 128 (7.7) | 78* (60.9%) | 516 (7.2) | 323* (62.6) | 0.806 |
| LSIL | 168 (10.2) | 642 (9.0) | 0 | ||
| ASC-H | 9 (0.5) | 35 (0.5) | 0 | ||
| HSIL | 29 (1.8) | 108 (1.5) | 0 | ||
| Endo/Glandular | 0 (0.0) | 1 (0.0) | 0 | ||
| Inadequate | 15 (0.9) | 37 (0.5) | 0 | ||
| Totals | 1653 | 78 (60.9%) | 7145 | 327 (63.8) | |
Abbreviations: NILM = negative for intraepithelial lesion or malignancy, ASC-US = atypical squamous cells of undetermined significance, LSIL = low grade squamous intraepithelial lesion, ASC-H = atypical squamous cells of undetermined significance, high grade HSIL = high grade squamous intraepithelial lesion, Endometrial/Glandular = combined cytology categories with glandular lesions, Unsatisfactory = unsatisfactory for evaluation.
Prior to July 1, 2018, screening practice at MSDH consisted of cytology with HPV triage of women with a diagnosis of ASC-US for women of all ages. MSDH switched to HPV and cytology co-testing for women aged 30+ as of July 1, 2018
Contains a missing HPV test., The HPV test was not available for evaluation. A total of 90 HPV tests are missing in all.